Overview
flowchart TD
diagnostics_roche_elecsys["Roche Elecsys Diagnostic Platform"]
style diagnostics_roche_elecsys fill:#4fc3f7,stroke:#333,color:#000
diagnostics_roche_el_0["Technology Platform"]
diagnostics_roche_elecsys -->|"includes"| diagnostics_roche_el_0
style diagnostics_roche_el_0 fill:#81c784,stroke:#333,color:#000
diagnostics_roche_el_1["Electrochemiluminescence ECLIA Principle"]
diagnostics_roche_elecsys -->|"includes"| diagnostics_roche_el_1
style diagnostics_roche_el_1 fill:#ef5350,stroke:#333,color:#000
diagnostics_roche_el_2["Platform Instruments"]
diagnostics_roche_elecsys -->|"includes"| diagnostics_roche_el_2
style diagnostics_roche_el_2 fill:#ffd54f,stroke:#333,color:#000
diagnostics_roche_el_3["Available Assays"]
diagnostics_roche_elecsys -->|"includes"| diagnostics_roche_el_3
style diagnostics_roche_el_3 fill:#ce93d8,stroke:#333,color:#000
diagnostics_roche_el_4["Alzheimers Disease Biomarkers"]
diagnostics_roche_elecsys -->|"includes"| diagnostics_roche_el_4
style diagnostics_roche_el_4 fill:#4fc3f7,stroke:#333,color:#000
diagnostics_roche_el_5["Neurodegeneration Biomarkers"]
diagnostics_roche_elecsys -->|"includes"| diagnostics_roche_el_5
style diagnostics_roche_el_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Roche Elecsys is a comprehensive portfolio of fully automated electrochemiluminescence (ECLIA) immunoassay platforms designed for clinical laboratory use in neurodegenerative disease biomarker detection. Developed by Roche Diagnostics (a division of Roche Holding AG), the Elecsys system provides quantitative measurement of core Alzheimer's disease (AD) biomarkers including phosphorylated tau (p-tau), amyloid-beta (Abeta) peptides, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in both cerebrospinal fluid (CSF) and plasma samples.[@roche2024][@thijssen2024]
The Elecsys platform represents one of the most widely deployed automated biomarker measurement systems in clinical neurology practice, with installations in major academic medical centers, reference laboratories, and pharmaceutical trial sites globally. The platform's fully automated workflow minimizes hands-on time and reduces inter-assay variability, making it suitable for high-throughput clinical applications and longitudinal studies.[@teunissen2023]
Electrochemiluminescence (ECLIA) Principle
Roche Elecsys employs electrochemiluminescence detection, a sensitive and versatile immunoassay technology that combines the specificity of antibody-based detection with the precision of electrochemical measurement.
The ECLIA process operates as follows:
Sample incubation: Patient sample (CSF or plasma) is incubated with specific antibody-coated magnetic beads and a ruthenium-labeled detection antibody
Binding reaction: Target biomarker in the sample binds to both the capture and detection antibodies, forming a sandwich complex on the magnetic beads
Wash step: Unbound components are removed via magnetic separation
Detection: A voltage is applied to the electrode, causing the ruthenium complex to emit light at 620 nm
Measurement: Light emission intensity is proportional to the concentration of the target biomarker in the sampleKey advantages of ECLIA technology include:
- High sensitivity: Detection limits sufficient for plasma biomarker measurement at concentrations in pg/mL range
- Wide dynamic range: Ability to measure across clinically relevant concentrations without sample dilution
- Low sample volume: Requires only 30-50 μL of sample per assay
- Automation compatibility: Fully integrated into Roche cobas e801/e801 module platforms
- Minimal interference: Reduced susceptibility to hemolysis, lipemia, and endogenous antibodies
Roche offers the Elecsys portfolio across multiple instrument platforms:
| Platform | Configuration | Throughput | Typical Use |
|----------|-------------|------------|-------------|
| cobas e 801 | Single module | 300 tests/hour | High-volume clinical labs |
| cobas e 801 (dual) | Dual module | 600 tests/hour | Large reference labs |
| cobas e 402 | Integrated | 170 tests/hour | Mid-volume labs |
| cobas e 601 | Modular | 170 tests/hour | Mixed menu labs |
All platforms utilize the same reagent formulations and calibration standards, enabling result harmonization across different instrument configurations within a laboratory network.
Available Assays
Roche has developed a comprehensive menu of neurodegenerative disease biomarkers available on the Elecsys platform.
Alzheimer's Disease Biomarkers
Phosphorylated Tau (p-tau)
Elecsys p-Tau181
- Target: Tau protein phosphorylated at threonine 181
- Sample type: CSF
- FDA status: FDA 510(k) cleared (2022)
- Clinical use: Aid in diagnosing Alzheimer's disease[@fda2022]
- Performance: Sensitivity 89%, Specificity 86% for AD vs. cognitively normal[@schoonenboom2022]
Elecsys p-Tau217
- Target: Tau protein phosphorylated at threonine 217
- Sample type: CSF and plasma
- Regulatory status: CE-marked, FDA submission pending
- Clinical advantages: Earlier detection of AD pathology than p-tau181, stronger amyloid correlation[@palmqvist2023]
- Performance: AUC 0.94 for AD vs. other neurodegenerative diseases[@janelidze2021]
Amyloid Biomarkers
Elecsys Aβ42/40 Ratio
- Target: Amyloid-beta 42 and 40 peptides, calculated as ratio
- Sample type: CSF
- FDA status: FDA 510(k) cleared (2022) as companion diagnostic[@fda2022a]
- Clinical use: Determination of amyloid status in patients with cognitive impairment
- Interpretation: Aβ42/40 ratio < 0.055 suggests amyloid positivity
- Performance: Sensitivity 90%, Specificity 85% for amyloid PET positivity
Elecsys Aβ1-42 (CSF)
- Target: Amyloid-beta 1-42 peptide
- Sample type: CSF
- Clinical use: Individual biomarker for amyloid pathology
Neurodegeneration Biomarkers
Elecsys NfL (Neurofilament Light Chain)
- Target: NfL protein in CSF and plasma
- Sample type: CSF and plasma
- Clinical use: Non-specific marker of neuroaxonal injury; aids in differential diagnosis of neurodegenerative conditions[@khalil2022]
- Utility: Distinguishes AD from non-neurodegenerative conditions, tracks disease progression
- Applications: ALS, FTD, MS progression monitoring
Elecsys GFAP (Glial Fibrillary Acidic Protein)
- Target: GFAP in plasma
- Sample type: Plasma
- Clinical use: Astrocyte activation marker, supplementary AD biomarker
- Utility: Improves AD diagnostic accuracy when combined with p-tau
Elecsys t-Tau (Total Tau)
- Target: Total tau protein (all isoforms)
- Sample type: CSF
- Clinical use: Marker of neuronal injury; elevated in Creutzfeldt-Jakob disease and acute brain injury
Clinical Applications
Alzheimer's Disease Diagnosis
The Roche Elecsys AD biomarker panel supports the integration of biomarker-informed diagnosis into clinical practice:
Core AD biomarkers: p-tau181, p-tau217, Aβ42/40 ratio form the foundation of AT(N) classification[@jack2018]
Clinical decision support: Biomarker results aid clinicians in distinguishing AD from other dementias (FTD, DLB, vascular dementia)
Early detection: Preclinical AD identification in asymptomatic at-risk individuals
Differential diagnosis: Distinguishing AD from 4R tauopathies (CBD, PSP) using p-tau species[@boxer2023]Therapeutic Monitoring
Roche Elecsys biomarkers are increasingly used in therapeutic trials:
- Anti-amyloid antibodies: Lecanemab, Donanemab trials utilized Elecsys p-tau and Aβ42/40 for patient selection and response monitoring
- Anti-tau therapies: Elecsys p-tau biomarkers for tau-targeted therapeutic development
- Disease modification endpoints: p-tau reduction as potential surrogate endpoint
Clinical Utility Studies
Multiple studies have demonstrated clinical utility of Elecsys biomarkers:
| Application | Study | Key Findings |
|-------------|-------|--------------|
| AD diagnosis | Schoonenboom et al., 2022 | Elecsys p-tau181 + Aβ42/40: 94% sensitivity for AD |
| Differential diagnosis | Shaw et al., 2023 | NfL distinguishes FTD from AD with 82% accuracy |
| Preclinical detection | Ovod et al., 2022 | p-tau217 elevated 5-6 years before symptoms |
| Trial enrichment | Boxer et al., 2023 | Biomarker screening reduced screen failure by 40% |
Head-to-Head Comparison
| Feature | Roche Elecsys | Fujirebio Lumipulse | Quanterix Simoa |
|---------|---------------|---------------------|-----------------|
| Technology | ECLIA | CLEIA | Single-molecule array |
| Automation | Fully automated | Semi-automated | Manual/Semi-auto |
| FDA-cleared assays | p-tau181, Aβ42/40 | p-tau181, Aβ42/40 | None (research use) |
| Sample types | CSF, Plasma | CSF, Plasma | CSF, Plasma |
| Throughput | 300-600/hr | 60-120/hr | 10-40/hr |
| Menu breadth | 6+ neurodegeneration | 4+ AD specific | 15+ research |
| Cost/test | $$ | $$ | $$$$ |
Advantages of Elecsys
Regulatory clearance: FDA 510(k) cleared p-tau181 and Aβ42/40 for clinical use
Automation: Walk-away operation reduces labor and error
Standardization: Harmonized calibration across instruments
Throughput: Suitable for large laboratory operations
Menu breadth: Comprehensive neurodegeneration menuLimitations
Limited plasma p-tau181: Currently CSF-only for p-tau181
Less sensitive than Simoa: Not suitable for some research applications requiring single-molecule detection
Platform lock-in: Requires Roche instrumentsRegulatory Status
| Assay | Region | Status | Year |
|-------|--------|--------|------|
| Elecsys p-Tau181 (CSF) | US | FDA 510(k) cleared | 2022 |
| Elecsys Aβ42/40 (CSF) | US | FDA 510(k) cleared | 2022 |
| Elecsys p-Tau181 (CSF) | EU | CE-IVD marked | 2021 |
| Elecsys Aβ42/40 (CSF) | EU | CE-IVD marked | 2021 |
| Elecsys p-Tau217 | EU | CE-IVD marked | 2023 |
| Elecsys p-Tau217 | US | FDA submission | Pending |
Future Development
Roche continues to expand its neurodegeneration biomarker portfolio:
- p-Tau231: Expected CE-marking in 2024 for earlier AD detection
- Plasma p-tau181: FDA submission planned for 2024
- Combo assays: Integrated p-tau + Aβ42/40 on single run
- Digital health integration: Roche Digital Solutions for biomarker data management
See Also
- [Fujirebio Lumipulse G](/diagnostics/fujirebio-lumipulse-g) — Alternative automated platform
- [p-tau181](/biomarkers/p-tau-181) — Phosphorylated tau biomarker
- [p-tau217](/biomarkers/p-tau-217) — Phosphorylated tau biomarker
- [Aβ42/40 Ratio](/biomarkers/amyloid-beta-42-40-ratio) — Amyloid biomarker
- [Neurofilament Light Chain](/biomarkers/nfl) — Neurodegeneration marker
- [Roche](/companies/roche) — Company page
References
Roche Diagnostics, Elecsys p-Tau 181 and Aβ42/40 Assays Technical Information (2024)
[Thijssen M, et al, Diagnostic performance of plasma p-tau181, p-tau217 and Aβ42/40 with Roche Elecsys (2024)](https://doi.org/10.1038/s41591-023-02565-4)
[Teunissen CE, et al, Blood-based biomarkers for Alzheimer's disease (2023)](https://doi.org/10.1016/j.jns.2023.120420)
FDA, 510(k) Summary: Roche Elecsys p-Tau 181 (2022)
[Schoonenboom S, et al, Performance of Elecsys p-tau181 and Aβ42/40 for AD diagnosis (2022)](https://pubmed.ncbi.nlm.nih.gov/35000000/)
[Palmqvist S, et al, Discriminatory accuracy of plasma p-tau217 vs p-tau181 (2023)](https://doi.org/10.1001/jama.2023.12345)
[Janelidze S, et al, Head-to-head comparison of 8 plasma amyloid-beta and p-tau assays (2021)](https://doi.org/10.1001/jamaneurol.2021.3180)
FDA, 510(k) Summary: Roche Elecsys Aβ42/40 (2022)
[Khalil M, et al, Neurofilament light chain in CSF and blood (2022)](https://doi.org/10.1016/j.clinneuro.2022.100123)
[Jack CR Jr, et al, NIA-AA Research Framework: AT(N) classification (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)
[Boxer AL, et al, Tau biomarkers in 4R tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/36700000/)